Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. There pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. There pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response
Recent Articles
- Understanding O'Leary’s Insights on Wealthy Investment Practices
- Calidi Biotherapeutics Secures $6.9 Million in Offering Success
- Understanding GeneDx Holdings Corp. Legal Issues and Investor Rights
- Investors Urged to Act Before SelectQuote Class Action Deadline
- Class Action Suit for Snap Inc. Investors - Key Insights
- Spectrum Pharmaceuticals Faces Class Action: Investors Act Now
- Investors Urged to Seek Counsel Ahead of Class Action Deadline
- Porsche Classic Restoration Challenge Celebrates Timeless Craftsmanship
- Legal Support Available for Vera Bradley Investors Facing Losses
- Turning $1000 into Over $2500: The Spotify Investment Journey
- PulteGroup's Investment Performance: A 5-Year Review
- Celebrating Excellence: 241 Student-Athletes Honored at Florida Southern
- Cobre del Mayo, S.A. de C.V. Completes Exchange Offer Successfully
- Celebrating Timeless Craftsmanship in the Porsche Restoration Challenge
- Exciting Groundbreaking for Whitman Villas by EPM Announced
- Blazing Star Merger Extends Tender Offer for Walgreens Notes
- Calidi Biotherapeutics Raises $6.9 Million to Advance Therapies
- Revolutionizing Supplier Financing with Vendor Pay Express
- Nick Brien Takes Helm as CEO, Strengthening OUTFRONT Media
- Investing in Cadence Design Systems: A 5-Year Growth Story
- New York Court Overturns Unjust Fine Against President Trump
- Empowering Change: The Upcoming Rare Diseases Summit
- Transforming Dairy Health: A New Partnership for Genetic Upgrades
- Celebrating 60 Years of Progress in Xizang's Development
- Exciting Developments at Hancock Gateway Park in Indiana
- Understanding Cheesecake Factory's Performance Metrics
- Exploring Robotics Stocks Beyond Just AI Heavyweights
- A Decade of Growth: The Transformation of Live Nation Entertainment
- Edison Electric Institute Welcomes New Leadership Team Members
- Exploring the Uveal Melanoma Market: Trends and Future Outlook
- Amazon's Technical Optimism Signals Potential Upward Momentum
- Experience Homeownership with LGI Homes at Neuse Ridge
- Regional Health Properties' Financial Triumph in 2025 Q2 Results
- ROHM Unveils Innovative Power Supply Reference Design System
- Eli Lilly's Legal Troubles: What Investors Need to Know
- Explore the New Homes at Neuse Ridge by LGI Homes
- Sensus Healthcare Faces Securities Fraud Investigation by Legal Experts
- Lucid Group's 1-For-10 Reverse Split: Market Impact and Insights
- Nanalysis Scientific Corp. Plans a Q2 Conference Call Announcement
- Discover the Leading PPM Software Solutions for 2025
- Transformative Insights on VEGFR-2 Inhibitors in Oncology
- Pivot Bio Partners to Enhance Sustainable Agriculture Practices
- BioSyent Announces Exciting Dividend for Shareholders
- Timbercreek Financial Announces Monthly Dividend for Investors
- Parker Hannifin Announces Quarterly Dividend and Buyback Boost
- LKQ Corporation Welcomes John Mendel as New Chairman
- Northview Residential REIT Announces Upcoming Distribution Payment
- Understanding Recent Concerns for Solutions and Support, Inc.
- Secure Legal Counsel: Capricor Therapeutics Class Action Update
- SNC and Red 6 Team Up for Revolutionary Pilot Training System